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V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)We are grateful for Dr. Janoueix-Lerosey and colleagues pointing
out the labelling mistakes in Figure 1 on our original publication [1].
We apologize for the confusion these mistakes have caused and
have published a Corrigendum to correct them, together with extra
discussion and methods [2]. These changes do not affect the conclu-
sions of the manuscript. We do not agree with the Letter authors’
other considerations. We have presented our points to the editor
and the survival data in question has been further revised by two
independent reviewers after publication (one with clinical expertise
and one with statistical expertise), making us confident of the data
and approaches presented in the manuscript. For the two latter
points in the Letter: (3) We have further clarified our patient classi-
fication strategy based on CD44 expression, including the use of the
Kaplan-scan feature and the averaged 10% expression threshold
used. The analysis has been performed with a setting of minimum 8
patients per group as can be observed in Fig. 1 and replicated with
the original data. There might be a disparity of opinion about howpatients should be classified, but no statistical methodology con-
cern; (4) All survival curves show significance using the LogRank
test, although small degrees of significance are achieved due to lim-
ited samples per group. Significance can also be achieved when con-
sidering high or low CD44 expression in the context of other clinical
parameters, like for example in patients with age higher than 18
months at diagnosis, with or without NMYC amplification Figure 1
(Fig. 1). We have observed in many cases an association of CD44
high expression with worst outcome, and we suggest this can be
related to the presence of CD44-high undifferentiated cells. As dis-
cussed and referenced in our manuscript, the association between
low CD44 expression and bad outcome, pointed out by the Letter,
has been known for some time, but controversy remained in the
field as some aggressive tumours were known to present high CD44
expression. We specifically investigate the survival of patients with
the highest CD44 expression. We have discussed throughout the
paper the potential significance of this double role for CD44 expres-
sion in neuroblastoma and attribute it to the presence of different
CD44 expressing cell entities in neuroblastoma tumours. For this
reason, we are not to establish CD44 as a prognostic biomarker by
itself, and this is not the aim of the manuscript.
Fig. 1. a, Survival curves on dataset GSE45547 showing overall survival probability for tumours with high vs low CD44 when considering patients with more than 18 moths at diag-
nosis with MYCN amplification. tumour samples only. b, Survival curves showing overall survival probability for tumours with high CD44 vs rest when considering patients with
more than 18 moths at diagnosis without MYCN amplification. Patient samples per group are shown in brackets. p values: Logrank.
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